NovaSAID AB is a Swedish research
company developing drugs for diseases associated with inflammation,
pain and fever such as Rheumatoid Arthritis and Osteoarthritis.
The company’s objective is to develop innovative small-molecule
compounds that inhibit the mPGES-1 enzyme. mPGES-1 is linked to
several pathological conditions, e.g. chronic and acute inflammation,
pain, fever, anorexia, atherosclerosis, stroke and cancer.
The company’s goal is to develop a new generation of NSAIDs
to the point of clinical proof of concept. The company is open to
strategic partnership or project licensing discussions.